Eribulin Plus Anlotinib for HER2-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with breast cancer that has spread or cannot be surgically removed
- Your cancer is HER2-negative (a specific protein marker on cancer cells)
- You have received prior chemotherapy with certain drugs (anthracyclines or taxanes) and have progressed on or could not tolerate an antibody-drug conjugate treatment
- You have had no more than 4 previous chemotherapy treatments
- You have at least one measurable tumor lesion that can be tracked on imaging
- Your overall health and organ function (blood counts, liver, kidney) meet specific thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve treatment for advanced triple-negative breast cancer. It may reduce side effects and help you tolerate treatment better.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This trial is testing a drug called eribulin (given alone or with other drugs) for people with advanced HER2-negative breast cancer that has already been treated with an ADC (antibody-drug conjugate). The goal is to see if this new treatment can help control the cancer and potentially shrink tumors.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.